Biopharma is entering a new kind of “cliff”—not just the patent cliff, but the operational cliff that comes with it.
When exclusivity ends, the market doesn’t simply get cheaper. It gets faster. Generics and authorized competitors move quickly, pricing…
One-shot strategy: How to pick the right drug patent for maximum extension value
Most pharma teams don’t lose patent value because they miss the science. They lose it because they miss the timing—and the math—behind patent term extension.
Here’s the un…
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »
Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way of reading patent claims like a map, stress-testing your formulation pl…
Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …
Pharma has a $300 billion question it can’t afford to misread: Is the “clock” you’re counting really the one that matters?
In the patent world, timing isn’t just strategy—it’s survival. A few months can decide whether a blockbuster stays protected, whe…
Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…
Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the game.
Eurasia looks familiar on the surface—markets, regulators, patents, generics. But the rules of the road for drug patents across the r…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Pharmaceutical patent strategy is often discussed like a binary choice: cut, keep, or cash.
But in practice, it’s a portfolio decision—one that determines whether you’re funding growth or paying for “insurance” that never pays out.
In a recent piece fr…
The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t just a scheduling issue. It’s a revenue strategy. The moment a drug’s patent clock runs down, the market can shift from protected pricing to competitive pressu…
Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Next Product
In pharma, the hardest part of “innovation” isn’t the science—it’s the legal reality that follows it.
A promising launch can be derailed by a single overlooked patent, …
Get new actionable insights and updates from BiotechBlog
